Related Experiment Video
Updated: Feb 8, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
Do we need biomarkers for diabetics progressing to heart failure?
Kyriakos Dimitriadis1, Costas Tsioufis1, Dimitrios Tousoulis1
1First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
Summary
Glycemic variability, specifically in glycated hemoglobin A1c, independently predicts heart failure with preserved ejection fraction (HFpEF) in diabetic hypertensive patients. Understanding this link is crucial for managing cardiovascular risk.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Cardiovascular diseases like arterial hypertension and diabetes increase heart failure (HF) risk.
- Heart failure with preserved ejection fraction (HFpEF) is common with glucose dysregulation and high hemodynamic load.
- Predicting HFpEF incidence is a significant clinical challenge.
Discussion:
- Glycemic variability offers a novel dynamic metric for assessing glycemia's impact.
- The study investigated the association between glycated hemoglobin A1c variability and HFpEF development.
- Hypertensive patients with diabetes were the focus population.
Key Insights:
- Glycated hemoglobin A1c variability is independently associated with HFpEF incidence.
- This finding holds true for patients with both hypertension and diabetes.
- Glycemic control variability emerges as a critical factor in HFpEF prediction.
Outlook:
- Further research is needed to explore the impact of various antidiabetic therapies.
- Optimizing glycemic control variability management is essential for reducing HFpEF risk.
- Modern cardiology must integrate these insights for comprehensive patient care.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
978
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
978
01:17Pathophysiology of Heart Failure
3.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
01:27Heart Failure I: Introduction
927
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
927
01:22Heart Failure VI: Adjunct Therapies
368
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
01:22Heart Failure Drugs: Diuretics
990
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
990
01:30Heart Failure V: Medical Management
342
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
342